Metalloproteinases mediate diabetes-induced retinal neuropathy and vasculopathy

Area of Science:

• Ophthalmology
• Molecular Biology
• Biochemistry

Background:

• Diabetic retinopathy (DR) is a leading cause of blindness, characterized by complex pathological processes.
• Matrix metalloproteinases (MMPs) and metalloproteinases with a disintegrin domain (ADAMs) are crucial enzymes involved in tissue remodeling and signaling.
• These proteases play significant roles in both normal ocular development and various retinal disease states.

Purpose of the Study:

• To review current data on the involvement of MMPs and ADAMs in retinopathies, with a focus on diabetic retinopathy.
• To elucidate the specific roles of MMPs and ADAMs in the pathogenesis of proliferative diabetic retinopathy.
• To explore the potential of targeting these proteases for therapeutic interventions in retinal diseases.

Main Methods:

• Literature review of recent data on MMPs and ADAMs in retinopathies.
• Analysis of the molecular mechanisms underlying MMP and ADAM activity in diabetic retinopathy.
• Examination of the interplay between MMPs, ADAMs, and tissue inhibitors of metalloproteinases (TIMPs).

Main Results:

• MMPs and ADAMs contribute to angiogenesis, neuroinflammation, and blood-retina barrier breakdown in diabetic retinopathy.
• Pro-MMP-9 activation, stimulated by inflammation, hypoxia, and oxidative stress, exacerbates DR pathology.
• These enzymes are implicated in photoreceptor loss and the destruction of neuroprotective factors like prominin-1.

Conclusions:

• MMPs and ADAMs are critical mediators in the progression of diabetic retinopathy and other retinopathies.
• Tissue inhibitors of metalloproteinases (TIMPs) play a role in regulating proteolysis and signaling.
• Targeting MMPs and ADAMs with inhibitors presents a promising therapeutic avenue for vision restoration and neuroprotection.